Drugmaker GlaxoSmithKline will tighten its continuing medical-education funding rules in 2010 with financial support going only to independently designed and executed programs, company officials said in a news release.
“GSK will not support as many medical education programs, but we will continue funding those with the greatest potential to improve patient health,” said Deirdre Connelly, president of Glaxo North American Pharmaceuticals. The move, she added, is part of the drugmaker's effort to be more transparent in its business operations and interactions with healthcare providers.
The new policy will restrict eligible CME grant applicants to academic medical centers and their affiliated teaching and patient-care institutions, as well as national professional medical associations. Glaxo said it will no longer fund CME delivered by commercial providers such as medical education and communication companies. The drugmaker will continue posting all approved grants to its company Web site.